T-Cell Vaccination in Multiple Sclerosis (MS)

Sheba Medical Center

Status and phase: Unknown; Phase 2; Phase 1

Conditions: Multiple Sclerosis

Treatments: Biological: T-Cell Vaccination

Study type: Interventional

Funder types: Other

Identifiers

NCT00220428

SHEBA-98-1754-AA-CTIL

Details and patient eligibility

About

The purpose of this study is to evaluate the safety of T-cell vaccination in MS patients.

Full description

Immunization of MS patients with irradiated autologous encephalitogenic myelin peptides (EMP) specific T-cell lines or clones.

Clinical immunologic and neuroradiologic evaluation.

Sex: All

Ages: 16 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Definite MS (post criteria)
• Relapsing remitting or primary progressive clinical course. At least one relapse in the last two years.
• Disease duration > 1 year
• Expanded Disability Status Scale (EDSS) between 0-6
• Brain magnetic resonance imaging (MRI) compatible with MS
• Not involved in any other clinical trials
• No other systemic disease

Exclusion criteria

• Does not comply with the above

Trial design

Primary purpose: Educational/Counseling/Training

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)